[Monitoring drug therapy in venous thrombosis].
Minimal prerequisites for the follow-up of thrombolytic therapies are determinations of partial thromboplastin time, thrombin time and fibrinogen concentration. With help of these tests it is possible to lower the risk of rethromboses and haemorrhages. By including additional tests some patients may benefit in respect of safety and better knowledge of the underlying mechanisms. However, until now there exists no laboratory tests that is able to give information about success or failure of the therapy independent of phlebography. For the gentechnological products like tPA and prourokinase final conclusions can be drawn only after having established dose-response curves for patients suffering from thromboses.
D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011183:Postoperative Complications / Q000188:drug therapy*; D012008:Recurrence; D012306:Risk; D013924:Thrombophlebitis / Q000188:drug therapy*
D005343:Fibrinolytic Agents
Uberwachung der medikamentösen Therapie der Venenthrombose.